Nasdaq:US$19.15 (-0.41) | HKEX:HK$30.70 (-0.15) | AIM:£3.10 (+0)
搜索
新聞中心及演示文稿

中國香港、上海和美國新澤西州：2022年4月27日，星期一：和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或「本公司」）（納斯達克/倫敦證交所：HCM；香港交易所：13）今天宣佈，於 2022 年 4 月 27 日舉行之股東週年大會（「股東週年大會」）上提呈之普通決議案及特別決議案均獲正式通過。決議案之投票表決結果如下:

普通決議案 票數 (%)* 股東通過
贊成 反對 棄權 #
1. 考慮及接納截至2021年12月31日止年度之經審核財務報表、董事會報告及獨立核數師報告。

686,224,906

(99.9996%)

2,960

( 0.0004%)

 7,697,445 是
2(A). 重選杜志強先生為董事。

635,955,913

(92.4452%)

51,971,563

(7.5548%)

 5,997,835 是
2(B). 重選蘇慰國博士為董事。

686,123,331

(99.7377%)

1,804,145

(0.2623%)

 5,997,835 是
2(C). 重選鄭澤鋒先生為董事。

685,947,446

(99.7122%)

1,980,030

(0.2878%)

 5,997,835 是
2(D). 重選艾樂德博士為董事。

684,647,400

(99.5232%)

3,280,076

(0.4768%)

 5,997,835 是
2(E). 重選施熙德女士為董事。

681,250,085

(99.0294%)

6,677,146

(0.9706%)

 5,998,080 是
2(F). 重選卡博樂先生為董事。

686,252,741

(99.7566%)

1,674,735

(0.2434%)

 5,997,835 是
2(G). 重選費凱寧醫生為董事。

687,778,031

(99.9783%)

149,445

(0.0217%)

 5,997,835 是
2(H). 重選蓆紀倫先生為董事。

674,126,615

(98.1141%)

12,957,617

(1.8859%)

 6,841,079 是
2(I). 重選莫樹錦教授為董事。

670,413,452

(97.4558%)

17,501,649

(2.5442%)

 6,010,210 是
3. 就香港財務報告及美國財務報告目的，分別委聘羅兵咸永道會計師事務所及普華永道中天會計師事務所（特殊普通合夥）為本公司核數師，並授權董事釐定核數師薪酬。

685,514,922

(98.7906%)

8,392,264

(1.2094%)

 18,125 是
特別決議案
4. 授予本公司董事一般性授權以發行額外股份。^

683,701,055

(99.3864%)

4,221,351

(0.6136%)

 6,002,905 是
普通決議案
5(1). 授予本公司董事一般性授權以購回本公司股份。^

687,914,356

(99.9989%)

7,770

( 0.0011%)

 6,003,185 是
5(2). 更新長期獎勵計劃項下的計劃授權限額。^

601,082,095

(91.7604%)

53,973,751

(8.2396%)

 38,869,465 是

* 所有百分比皆計至小數點後 4 個位。
#    「棄權」票於法律上不屬投票，故於計算決議案的「贊成」及「反對」票比例時不計算在內。
^ 第 4 及 5 項決議案的全文載於股東週年大會通告內。

 

本公司所有董事（即杜志強先生、蘇慰國博士、鄭澤鋒先生、艾樂德博士、施熙德女士、卡博樂先生、費凱寧醫生、蓆紀倫先生及莫樹錦教授）均親身或以電子設施方式出席了股東週年大會。

附註：

  1. 賦予股份持有人出席股東週年大會權利，並於會上就全部決議案有表決權的股份總數：864,530,850 股。
  2. 賦予股份持有人出席股東週年大會權利，惟根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.40 條所載須放棄表決贊成決議案的股份總數：零股。
  3. 上市規則規定須於股東週年大會上放棄表決權的股份持有人所持股份總數：零股。
  4. 股東週年大會投票表決監票員為 Computershare Investor Services (Jersey) Limited（本公司的股份登記總處）。

 

關於和黃醫藥

和黃醫藥（納斯達克/倫敦證交所：HCM；香港交易所：13）是一家處於商業化階段的創新型生物醫藥公司，致力於發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。集團旗下公司共有超過 4,600 名員工，其中核心的腫瘤/免疫業務擁有約 1,500 人的團隊。自成立以來，和黃醫藥已將自主發現的 12 個候選癌症藥物推進到在全球開展臨床研究，其中首三個創新腫瘤藥物現已於中國獲批上市。欲瞭解更多詳情，請訪問： www.hutch-med.com或關注我們的 LinkedIn專頁。

Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 21, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on April 20, 2020 to the following persons discharging managerial responsibilities were vested on April 20, 2022:-

Award Holder   Number of American depositary shares (“ADS”)
Mr Simon To (Executive Director) 2,3971
Dr Dan Eldar (Non-executive Director (“NED”)) 2,397
Ms Edith Shih (NED) 2,3972
Mr Paul Carter (Independent Non-executive Director (“INED”)) 2,0373
Dr Karen Ferrante (INED) 2,397
Mr Graeme Jack (INED) 2,397
Professor Tony Mok (INED) 2,397
Notes:
      1. Similar to the arrangement for his Director’s fees, these ADSs were not received by Mr Simon To, but were received by or for the account of his employer, Hutchison Whampoa (China) Limited.
      2. Similar to the arrangement for her Director’s fees, these ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.
      3. Mr Paul Carter elected, on acceptance of the grant of his awards, to have 15% of his LTIP awards (amounting to US$7,500 with respect to his awards which vested on April 20, 2022) held on his behalf by the trustee administering the LTIP pending vesting in the form of cash, to settle his tax liabilities in respect of his awards.

 

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

 

(a) Dr Dan Eldar

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Dan Eldar
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(b) Mr Paul Carter

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Paul Carter
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,037 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(c) Dr Karen Ferrante

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Karen Ferrante
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(d) Mr Graeme Jack

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Graeme Jack
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

(e) Professor Tony Mok

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Professor Tony Mok
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code		 ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,397 ADS
d) Aggregated information

  • Aggregated volume
  • Price
 N/A
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786

Media Enquiries
Americas – Brad Miles,
Solebury Trout		 +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe – Ben Atwell / Alex Shaw,
FTI Consulting		 +44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia – Zhou Yi,
Brunswick		 +852 9783 6894 (Mobile)
HUTCHMED@brunswickgroup.com

Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited		 +44 (20) 7886 2500